Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in May 2016 on request of the Sponsor.
On 19 June 2013, orphan designation (EU/3/13/1146) was granted by the European Commission to Sucampo Pharma Europe Ltd, United Kingdom, for unoprostone isopropyl for the treatment of retinitis pigmentosa.
The sponsorship was transferred to Wainwright Associates Ltd, United Kingdom, in July 2015.
Treatment of retinitis pigmentosa
|Date of designation||
|Orphan designation status||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.